Sector footprint
$4.9M in exports
Reported chemicals exports in 2024 across 21 qualifying HS6 products.
Sector export playbook ยท HS 28-38
Explore Armenia's HS 28-38 product portfolio, buyer markets, growth signals, and diversification opportunities. Use this guide to prioritize research, not to treat calculated indicators as guaranteed sales.
Chemicals capability
Compare exporter scale with product breadth, buyer demand, growth, and destination reach. A large sector does not remove the need for product, compliance, pricing, and buyer validation.
Sector footprint
Reported chemicals exports in 2024 across 21 qualifying HS6 products.
Global demand
The sector's reported buyer import base provides context for product and market prioritization.
How to use the guide
Start with products that combine demand and exporter capability, then validate standards, route economics, buyers, and competition.
Product portfolio
Each HS6 product is ranked by calculated opportunity and shown with reported market size, exporter exports, growth, and destination reach.
| Product | Global size | Your exports | Opportunity | CAGR | Markets | Share |
|---|---|---|---|---|---|---|
| HS 300490Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $297.5B | $1.7M | $112.6B | -1.4% | 22 | +0.0% |
| HS 293359Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea (barbituric acid) and its derivatives),and loprazolam, mecloqualone, methaqualone, zipeprol and salts thereof | $11.8B | $4.4K | $11.7B | +148.0% | 2 | +0.0% |
| HS 330499Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $23.5B | $208.5K | $9.8B | +51.6% | 7 | +0.0% |
| HS 300212Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $17.7B | $9.6K | $8.7B | +27.8% | 3 | +0.0% |
| HS 382200Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $18.5B | $12.4K | $7.8B | +0.0% | 7 | +0.0% |
| HS 293499Nucleic acids and their salts, other heterocyclic compounds, n.e.c. in heading number 2934 | $11.9B | $2.3K | $7.4B | -13.2% | 2 | +0.0% |
| HS 382499Chemical products, mixtures and preparations: n.e.c. heading 3824 | $11.7B | $1.8M | $7.0B | +44.0% | 4 | +0.1% |
| HS 330300Perfumes and toilet waters | $11.0B | $64.3K | $6.2B | +31.1% | 5 | +0.0% |
| HS 300215Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $15.9B | $871.0K | $5.4B | +385.4% | 3 | +0.0% |
| HS 300290Toxins, cultures of micro-organisms (excluding yeasts) and similar products | $5.5B | $26.5K | $3.1B | -7.3% | 4 | +0.0% |
| HS 300420Medicaments: containing antibiotics (other than penicillins, streptomycins or their derivatives), for therapeutic or prophylactic uses, packaged for retail sale | $3.8B | $0.3 | $2.0B | -94.7% | 1 | +0.0% |
| HS 284690Compounds, inorganic or organic (excluding cerium), of rare-earth metals, of yttrium, scandium or of mixtures of these metals | $1.4B | $1.6K | $1.5B | +10.4% | 1 | +0.0% |
| HS 281820Aluminium oxide: other than artificial corundum | $2.3B | $10.1K | $1.1B | +16.9% | 1 | +0.0% |
| HS 300439Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $2.7B | $2.0K | $1.1B | +48.1% | 2 | +0.0% |
| HS 330210Odoriferous substances and mixtures: of a kind used in the food or drink industries | $1.4B | $462.5 | $1.0B | +100.5% | 2 | +0.0% |
| HS 293299Heterocyclic compounds: with oxygen hetero-atom(s) only, no lactones or unfused furan rings (hydrogenated or not) in the structure, other than isosafrole, 1-(1,3-benzodiaxol-5-yl) propan-2-one, piperonal, safrole, tetrahydrocannabinols (all isomers) | $723.6M | $230.2 | $674.9M | +41.7% | 1 | +0.0% |
| HS 340600Candles, tapers and the like | $1.0B | $143.9K | $640.7M | +61.0% | 1 | +0.0% |
| HS 293379Heterocyclic compounds: lactams: other than 6-hexanelactam (epsilon caprolactam) | $1.3B | $6.9K | $627.6M | +23.7% | 1 | +0.0% |
| HS 293090Organo-sulphur compounds: n.e.s. in heading no. 2930 | $639.9M | $82.0 | $532.1M | +1.4% | 1 | +0.0% |
| HS 293134Organo-inorganic compounds: organo-phosphorus derivatives, sodium-3-(hydroxysilyl)propyl methylphosphonate | $323.1M | $4.6K | $522.7M | +20.7% | 1 | +0.0% |
| HS 340220Washing and cleaning preparations: surface-active, whether or not containing soap (excluding those of heading no. 3401), put up for retail sale | $2.0B | $15.6 | $510.2M | -72.2% | 1 | +0.0% |
Best markets
Markets are ranked by calculated opportunity across the qualifying products in this sector view.
USA
10 products represented in the sector.
$44.4B$123.7B reported buyer importsCHE
2 products represented in the sector.
$30.7B$49.0B reported buyer importsDEU
11 products represented in the sector.
$22.4B$58.8B reported buyer importsCHN
5 products represented in the sector.
$13.1B$31.8B reported buyer importsSVN
1 products represented in the sector.
$9.7B$7.6B reported buyer importsBEL
4 products represented in the sector.
$9.0B$21.9B reported buyer importsGBR
5 products represented in the sector.
$7.9B$23.5B reported buyer importsESP
4 products represented in the sector.
$7.7B$15.3B reported buyer importsNLD
4 products represented in the sector.
$7.1B$13.8B reported buyer importsJPN
4 products represented in the sector.
$5.9B$16.6B reported buyer importsCAN
3 products represented in the sector.
$5.7B$10.4B reported buyer importsRUS
4 products represented in the sector.
$5.2B$12.0B reported buyer importsGrowth stars
Average product-level CAGR is a screening signal. Confirm the latest trend, base effects, buyer quality, and commercial feasibility before acting.
| Product | Average CAGR | Opportunity | Markets |
|---|---|---|---|
| HS 300215Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | +385.4% | $5.4B | 3 |
| HS 293359Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea (barbituric acid) and its derivatives),and loprazolam, mecloqualone, methaqualone, zipeprol and salts thereof | +148.0% | $11.7B | 2 |
| HS 330210Odoriferous substances and mixtures: of a kind used in the food or drink industries | +100.5% | $1.0B | 2 |
| HS 340600Candles, tapers and the like | +61.0% | $640.7M | 1 |
| HS 330499Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | +51.6% | $9.8B | 7 |
| HS 300439Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | +48.1% | $1.1B | 2 |
| HS 382499Chemical products, mixtures and preparations: n.e.c. heading 3824 | +44.0% | $7.0B | 4 |
| HS 293299Heterocyclic compounds: with oxygen hetero-atom(s) only, no lactones or unfused furan rings (hydrogenated or not) in the structure, other than isosafrole, 1-(1,3-benzodiaxol-5-yl) propan-2-one, piperonal, safrole, tetrahydrocannabinols (all isomers) | +41.7% | $674.9M | 1 |
| HS 330300Perfumes and toilet waters | +31.1% | $6.2B | 5 |
| HS 300212Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | +27.8% | $8.7B | 3 |
Diversification opportunities
Destination count is a simple breadth indicator. It does not measure destination concentration or guarantee resilience.
HS 300490
HS 330499
HS 382200
HS 330300
HS 382499
HS 300290
HS 300212
HS 300215
Frequently asked questions
Practical guidance for interpreting sector scale, growth, product breadth, and buyer markets.
Compare sector exports, product breadth, buyer markets, growth, and global demand. These signals identify research priorities rather than guarantee market access.
Products with higher average reported growth in the screened rows. Validate the time period, base effects, buyer demand, and current exporter position.
Products reaching more buyer markets in the screened data. Destination breadth is useful context but does not replace concentration, route, or buyer analysis.
Data source
OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). OECD BIMTS is the primary trade series for this view. Supporting bilateral trade context uses CEPII BACI bilateral trade flows (202601) under Etalab 2.0 Open Licence. Yugalinks presents derived views of reported observations and calculated indicators. Data terms: OECD Terms & Conditions.